Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
151 Leser
Artikel bewerten:
(0)

Marken Launches Clinical Home Healthcare Services

Becomes the only clinical logistics provider with fully integrated services

RESEARCH TRIANGLE PARK, North Carolina, Aug. 20, 2019 /PRNewswire/ -- Marken announced today that its nursing services for home-based clinical trials are now operational in most key markets around the world, which can be integrated into its already well-established logistics network. The home healthcare offering extends its existing direct to patient logistics services. The expanded services will now include: clinical drug storage, direct-to-patient delivery, biologic sample collection, central pharmacy and home care / nursing services.

Marken Logo.

The new service has been developed in conjunction with all applicable regulations and guidelines which apply when running clinical trials in multiple countries. These regulations include: HIPAA and other internationally-equivalent data privacy laws, General Data Protection Regulation (GDPR) and validation of computer systems. New operating software and a new set of Standard Operating Procedures have been developed with strict training requirements. The new operating software will reduce the paper-based study visit documentation, enable real-time, secure document transmission and improve project oversight.

The new home healthcare services can be integrated with Marken's other services such as: storage of clinical drug product in its depot network, utilization of its central pharmacy services and coordination with its global courier services. These integrated services can be combined to create customizable, study specific solutions for increased quality and cost efficiency.

Wes Wheeler, CEO of Marken said, "We are excited to launch our new home healthcare service on a global scale. Decentralized clinical trials are becoming more common and we are working to ensure that we meet the needs of our clients as they transform their own industry. We see our home-based nursing network as an important new service which can improve patient recruitment, patient retention, and a more integrated solution."

About Marken
Marken is a wholly owned subsidiary of UPS. Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient and Home Health care services, biological sample shipments and offers a state-of-the-art GMP-compliant depot network and logistic hubs in 51 locations worldwide for clinical trial material storage and distribution. Marken's more than 1,000 staff members manage 80,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken's unique position in the pharma and logistics industry.

Logo - https://mma.prnewswire.com/media/732970/MARKEN_Logo.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2019 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.